Seattle Genetics Inc  SGEN
Data as of 07-29-2015 12:00 AM CT
Last PriceDay ChangeVolume
-1.64 (-3.34%)
Open PriceDay Range52-Wk Range
49.08 - 47.04
Mkt Cap($mil)YieldAvg Volume
 Stock Chart
Price Graph
 Key Stats
Morningstar Style BoxMid GrowthStock TypeDistressed
Market Cap $Mil5,907 Sales $Mil301
 Company Profile
What Does This Company Do?

Seattle Genetics is a development-stage biotech focused on the development of monoclonal antibody-based therapies. The firm's lead product, Adcetris, has received approval for relapsed/refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma, and the company has several other early-stage programs in trials. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Address21823 - 30th Drive South East
 Bothell, WA, 98021
Phone1 425 527-4000
Direct InvestmentNo
Dividend ReinvestmentNo
All quote data supplied by Morningstar Real-Time Data. Quotes for Nasdaq, NYSE and securities are delayed 20 minutes. © Copyright 2010 Morningstar, Inc.
Show Data Definitions
Become a Morningstar Premium Member. Enjoy our analyst picks and buy-sell opinions on 3,800 stocks, funds and ETFs. Learn more.

© Copyright 2015 Morningstar, Inc. All rights reserved. Morningstar, the Morningstar logo,, Morningstar Tools are either trademark or service marks of Morningstar, Inc.
Past performance is no guarantee of future results.
Returns will vary and shares may be worth more or less than their original cost when sold.